IN8bio, Inc. (INAB) financial statements and ratios from SEC XBRL: revenue $421000.00 (TTM), net margin -4617.6%, revenue growth 83.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $421000.00 |
| Net Margin | -4617.6% |
| Revenue Growth (YoY) | 83.0% |
| EPS Growth (YoY) | 678.9% |
| Price / Book | 0.68 |
| Price / Sales | 20.23 |
| FCF Yield | -84.4% |
| Altman Z-Score | -5.60 (distress) |
| Sector P/E (Healthcare) | 21.7 |
INAB overview · INAB earnings · INAB KPIs · INAB investor relations · INAB ownership · INAB peers · INAB filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.